{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-21-000024","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2021-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.487868+00:00","generated_at":"2026-06-28T17:16:26.309283+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Edwards Lifesciences Q3 sales up 15% to $1.3B; EPS $0.54; guidance reaffirmed","bullets":["Q3 sales $1.3B, up 15% reported (14% underlying); TAVR sales $858M, up 15% (14% underlying).","Adjusted EPS $0.54; full-year 2021 sales guidance unchanged at $5.2-$5.4B; adjusted EPS guided to high end of $2.07-$2.27.","TMTT sales $22M; company on track for U.S. approval of PASCAL platform for degenerative mitral regurgitation late 2022.","Free cash flow $471M in Q3, $1.1B YTD; cash and investments $3.1B, total debt $596M.","Q4 2021 guidance: sales $1.30-$1.38B, TAVR $850-$910M, adjusted EPS $0.53-$0.59."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-21-000024","json":"https://secwatch.observer/filing/0001099800-21-000024.json","markdown":"https://secwatch.observer/filing/0001099800-21-000024.md","text":"https://secwatch.observer/filing/0001099800-21-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980021000024/0001099800-21-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980021000024/ew-20211027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T17:16:26.309283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}